...In men with prostate cancer, long-term outcomes of androgen deprivation therapy are better with degarelix than with leuprolide, new trial data show.
The data are from a five-year extension of the 12-month phase III CS21 trial, in which degarelix (Firmagon) suppressed testosterone to castrate levels as effectively as -- but faster than - leuprolide (Lupron).....
The data are from a five-year extension of the 12-month phase III CS21 trial, in which degarelix (Firmagon) suppressed testosterone to castrate levels as effectively as -- but faster than - leuprolide (Lupron).....
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.